
CareDx (CDNA) Stock Forecast & Price Target
CareDx (CDNA) Analyst Ratings
Bulls say
CareDx Inc. demonstrated strong financial performance with a 25% increase in top-line revenue in Q4, driven by a 17% growth in volume and a 5% increase in average selling prices (ASPs), alongside record revenues from patient and digital solutions. The company maintained a positive trend in Q3, achieving a 21% top-line growth and recording its highest cash collections to date, indicating robust demand for its testing services. Additionally, CareDx's strategic expansion of its sales force is expected to further enhance volume growth, as reflected in a significant increase in kidney surveillance volumes and raised revenue estimates for 2026 and 2027, which now sit at $433 million and $485 million, respectively.
Bears say
CareDx Inc. has projected a negative revenue impact of $7.5 million in its 2026 guidance, primarily due to anticipated changes in reimbursement policies that could significantly affect its testing services. In Q3'25, the company's testing volume growth fell short of expectations, with 50,000 tests recorded, reflecting a seasonal slowdown despite a year-over-year increase in surveillance testing. Additionally, CareDx's stock trades at a concerning valuation of 1.4x and 1.7x its 2026 revenue estimates, considerably below historical averages of 3-7x and well behind current leaders in the diagnostics sector, indicating potential challenges in sustaining market competitiveness and profitability.
This aggregate rating is based on analysts' research of CareDx and is not a guaranteed prediction by Public.com or investment advice.
CareDx (CDNA) Analyst Forecast & Price Prediction
Start investing in CareDx (CDNA)
Order type
Buy in
Order amount
Est. shares
0 shares